Piper Sandler raised the firm’s price target on Amgen (AMGN) to $329 from $310 and keeps an Overweight rating on the shares. The firm notes the ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

Amgen (NASDAQ: AMGN) will present at the 35th Annual Oppenheimer Healthcare Life Sciences Conference at 11:20 a.m. ET on Wednesday, Feb. 12, 2025. Narimon Honarpour, senior vice president of global ...

Amgen is a biotechnology leader with competitive advantages in scale, R&D, manufacturing efficiency, and distribution, bolstered by a robust pipeline and rising margins. I currently rate Amgen as ...

Shares of Amgen Inc. AMGN shed 1.42% to $293.54 Friday, on what proved to be an all-around dismal trading session for the ...

The "Genomic Data Analysis and Interpretation Market Opportunities and Strategies to 2033" report has been added to ...

All of a sudden, Amgen stock is up 15% since late December to around $299. Its rise helped push up the healthcare sector up just over 7% since hitting a bottom in late December. The better-than ...

Company Announcement COPENHAGEN, Denmark; February 12, 2025 - Genmab A/S (Nasdaq: GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024 ...

Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...

In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other stocks that Jim Cramer discusses that are leading the Dow higher in 2025. On Thursday ...